Serna Bio
YC W21Ontario, US · Founded 2021 · 5 employees · 4 known investors
Serna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
Also known as Ladder Therapeutics (LTX)
AI & Machine LearningBiotechDeep TechHealthtechDrug discoveryUnited States of AmericaAmerica / CanadaFully Remote
Founders & leadership· Y Combinator alumni (W21)
Serna Bio was founded in 2021 by Rabia Khan.
RK
Rabia Khanin𝕏Founder/CEORabia Khan previously led machine learning efforts at Sensyne Health and worked at BenevolentAI. She now focuses on small-molecule RNA therapeutics.
Investors · 4
Founder mafia
2 people who came through Serna Bio went on to found or lead other companies.
Competitors · 10
by search overlap
Sionnatx29 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Syrna Therapeutics23 shared keywordsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
Sirnaomics20 shared keywordsSirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
Ronatherapeutics19 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Switch Therapeutics19 shared keywordsSwitch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Starnatx16 shared keywords星锐医药 (StarNA Tx) develops RNA-based therapeutics built around lipid nanoparticle (LNP) drug delivery systems. The company has created a library of thousands of lipid molecules and uses AI-based high-throughput screening to develop tissue-specific and cell-selective LNPs, including extrahepatic targeting and in-vivo CAR-T applications.
Day One Biopharmaceuticals16 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Siriusrna15 shared keywordsSirius is a biotech company developing RNAi-based therapies focused on cardiovascular diseases for global markets. It applies RNA interference technology to create new treatment options for patients.
ロゴマーク：AIRNA14 shared keywordsAIRNA develops RNA editing therapeutics aimed at providing functional cures for patients with rare diseases and common conditions. The company works in the genetic medicines and biotech space.
Serina Therapeutics13 shared keywordsSerina Therapeutics is a clinical-stage biotechnology company developing its POZ Platform, a polymer technology ("POZylation") that modifies proven small molecule drugs to enable controlled, sustained release with fewer side effects. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease, and the platform is also applied to CNS indications and RNA medicines.
Companies competing with Serna Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Serna Bio do?
- Serna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
- Who founded Serna Bio?
- Serna Bio was founded by Rabia Khan in 2021.
- Who are Serna Bio's investors?
- Serna Bio's investors include Backed, Hummingbird Ventures, Lifeforce Capital, Y Combinator.
- Where is Serna Bio headquartered?
- Serna Bio is headquartered in Ontario, US.